<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852644</url>
  </required_header>
  <id_info>
    <org_study_id>H-26701</org_study_id>
    <secondary_id>CDR0000635119</secondary_id>
    <nct_id>NCT00852644</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer</brief_title>
  <official_title>Feasibility and Outcome of Cyberknife® Precision Hypofractionated Radiosurgery for the Curative Management of Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less
      damage to normal tissue.

      PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic
      radiosurgery in treating patients with stage I or stage II non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To establish the maximum tolerated dose of CyberKnife® hypofractionated stereotactic
           radiosurgery in patients with medically inoperable, stage I or II non-small cell lung
           cancer.

        -  To establish the relationship between positron emission tomography (PET) response and
           local control and survival using fludeoxyglucose F 18 PET/CT imaging before treatment
           and at 1, 3, 6, and 12 months after treatment.

      OUTLINE: Patients undergo placement of 3 gold fiducial markers by CT-guidance or
      bronchoscopy. Patients then undergo CyberKnife® hypofractionated stereotactic radiosurgery
      over 45-120 minutes twice weekly for 2 weeks.

      Patients undergo fludeoxyglucose F 18 PET/CT scan at baseline and at 1, 3, 6, and 12 months
      after completion of treatment.

      After completion of study treatment, patients are followed periodically for up to 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor accrual
  </why_stopped>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Participants to receive Cyberknife radiation therapy in 4 doses over two weeks. Dose will be determined using a dose-escalation plan.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Who Did Not Experience a Dose Limiting Toxicity in the Less Than 3 Centimeter Cohort</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of Participants Who Did Not Experience a Dose Limiting Toxicity in the less than 3 centimeter cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose in the Less Than 3 Centimeter Cohort</measure>
    <time_frame>6 weeks</time_frame>
    <description>The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants Who Did Not Experience a Dose Limiting Toxicity in the More Than 3 Centimeter Cohort</measure>
    <time_frame>6 weeks</time_frame>
    <description>The number of participants that did not experience a dose-limiting toxicity in the greater than 3 centimeter cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose - More Than 3 Centimeter Cohort.</measure>
    <time_frame>6 weeks</time_frame>
    <description>The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Positron Emission Tomography (PET) Response and Local Control and Survival</measure>
    <time_frame>before treatment and at 1, 3, 6, and 12 months after treatment</time_frame>
    <description>Relationship between positron emission tomography (PET) response and local control and survival as measured by fludeoxyglucose F 18 PET/CT imaging</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>56 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>62 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>56 Gray (MORE than 3 centimeter cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>62 Gray (MORE than 3 centimeter cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68 Gray (MORE than 3 centimeter cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>Standard CT scans</description>
    <arm_group_label>56 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>62 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>68 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>56 Gray (MORE than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>62 Gray (MORE than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>68 Gray (MORE than 3 centimeter cohort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>standard doses with CT scans</description>
    <arm_group_label>56 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>62 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>68 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>56 Gray (MORE than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>62 Gray (MORE than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>68 Gray (MORE than 3 centimeter cohort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated radiation therapy</intervention_name>
    <description>4 doses over 2 weeks</description>
    <arm_group_label>56 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>62 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>68 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>56 Gray (MORE than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>62 Gray (MORE than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>68 Gray (MORE than 3 centimeter cohort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
    <description>CyberKnife radiosurgery</description>
    <arm_group_label>56 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>62 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>68 Gray (LESS than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>56 Gray (MORE than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>62 Gray (MORE than 3 centimeter cohort)</arm_group_label>
    <arm_group_label>68 Gray (MORE than 3 centimeter cohort)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed non-small cell lung cancer

               -  Stage I or II disease (T1-3, N0, M0)

                    -  T2 or T3 tumor ≤ 5 cm

                    -  No T3 tumors involving the central chest or mediastinum (only chest wall
                       involvement allowed)

          -  Tumor deemed technically resectable, in the opinion of an experienced thoracic
             surgeon, AND patient deemed &quot;medically inoperable&quot;

               -  Patients with fluorodeoxyglucose (FDG)-avidity in mediastinal lymph nodes are
                  eligible provided they are able to undergo mediastinoscopy to confirm N0 status

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for ≥ 6 months after
             completion of study treatment

        Exclusion Criteria:

          -  No history of contrast allergy

          -  No psychological issues that would preclude the completion of study treatment

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy or chemotherapy

          -  No suspected nodal metastasis that cannot be falsified by mediastinoscopy (i.e., hilar
             or mediastinal nodes that are either fludeoxyglucose F 18 [FDG]-avid or measure &gt; 1 cm
             in short axis diameter on CT scan)

          -  No tumor within or touching the proximal bronchial tree, defined as a volume of 2 cm
             in all directions around the proximal bronchial tree (carina, right and left main stem
             bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe
             bronchus, lingular bronchus, right and left lower lobe bronchi)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minh Tam Truong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University Cancer Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2009</study_first_posted>
  <results_first_submitted>February 13, 2017</results_first_submitted>
  <results_first_submitted_qc>December 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2018</results_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>Minh Tam Truong</investigator_full_name>
    <investigator_title>Chair and Associate Professor, Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>9 patients were enrolled onto this study between January 2009 and August 2012 in the Radiation Oncology Clinic at Boston Medical Center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>56 Gray (LESS Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks at 56 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
        <group group_id="P2">
          <title>62 Gray (LESS Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks at 62 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
        <group group_id="P3">
          <title>68 Gray (LESS Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks at 68 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
        <group group_id="P4">
          <title>56 Gray (MORE Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks at 56 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
        <group group_id="P5">
          <title>62 Gray (MORE Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks a 62 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
        <group group_id="P6">
          <title>68 Gray (MORE Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks at 68 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CyberKnife</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Who Did Not Experience a Dose Limiting Toxicity in the Less Than 3 Centimeter Cohort</title>
        <description>Number of Participants Who Did Not Experience a Dose Limiting Toxicity in the less than 3 centimeter cohort</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>56 Gray (LESS Than 3 Centimeter Cohort)</title>
            <description>Dose 1 (56 gray), less than 3 centimeter cohort</description>
          </group>
          <group group_id="O2">
            <title>62 Gray (LESS Less Than 3 Centimeter Cohort)</title>
            <description>Dose 2 (62 gray), less than 3 centimeter cohort</description>
          </group>
          <group group_id="O3">
            <title>68 Gray (LESS Than 3 Centimeter Cohort)</title>
            <description>Dose 3 (68 gray), less than 3 centimeter cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Did Not Experience a Dose Limiting Toxicity in the Less Than 3 Centimeter Cohort</title>
          <description>Number of Participants Who Did Not Experience a Dose Limiting Toxicity in the less than 3 centimeter cohort</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose in the Less Than 3 Centimeter Cohort</title>
        <description>The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.</description>
        <time_frame>6 weeks</time_frame>
        <population>The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.</population>
        <group_list>
          <group group_id="O1">
            <title>56 Gray (LESS Than 3 Centimeter Cohort)</title>
            <description>Dose 1 (56 gray), less than 3 centimeter cohort</description>
          </group>
          <group group_id="O2">
            <title>62 Gray (LESS Less Than 3 Centimeter Cohort)</title>
            <description>Dose 2 (62 gray), less than 3 centimeter cohort</description>
          </group>
          <group group_id="O3">
            <title>68 Gray (LESS Than 3 Centimeter Cohort)</title>
            <description>Dose 3 (68 gray), less than 3 centimeter cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose in the Less Than 3 Centimeter Cohort</title>
          <description>The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.</description>
          <population>The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.</population>
          <units_analyzed>dose</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>dose</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants Who Did Not Experience a Dose Limiting Toxicity in the More Than 3 Centimeter Cohort</title>
        <description>The number of participants that did not experience a dose-limiting toxicity in the greater than 3 centimeter cohort</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>56 Gray (MORE Than 3 Centimeter Cohort)</title>
            <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery
computed tomography: Standard CT scans
fludeoxyglucose F 18: standard doses with CT scans
hypofractionated radiation therapy: 4 doses over 2 weeks
stereotactic radiosurgery: CyberKnife radiosurgery</description>
          </group>
          <group group_id="O2">
            <title>62 Gray (MORE Than 3 Centimeter Cohort)</title>
            <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery
computed tomography: Standard CT scans
fludeoxyglucose F 18: standard doses with CT scans
hypofractionated radiation therapy: 4 doses over 2 weeks
stereotactic radiosurgery: CyberKnife radiosurgery</description>
          </group>
          <group group_id="O3">
            <title>68 Gray (MORE Than 3 Centimeter Cohort)</title>
            <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery
computed tomography: Standard CT scans
fludeoxyglucose F 18: standard doses with CT scans
hypofractionated radiation therapy: 4 doses over 2 weeks
stereotactic radiosurgery: CyberKnife radiosurgery</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Did Not Experience a Dose Limiting Toxicity in the More Than 3 Centimeter Cohort</title>
          <description>The number of participants that did not experience a dose-limiting toxicity in the greater than 3 centimeter cohort</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose - More Than 3 Centimeter Cohort.</title>
        <description>The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.</description>
        <time_frame>6 weeks</time_frame>
        <population>The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.</population>
        <group_list>
          <group group_id="O1">
            <title>56 Gray (MORE Than 3 Centimeter Cohort)</title>
            <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery
computed tomography: Standard CT scans
fludeoxyglucose F 18: standard doses with CT scans
hypofractionated radiation therapy: 4 doses over 2 weeks
stereotactic radiosurgery: CyberKnife radiosurgery</description>
          </group>
          <group group_id="O2">
            <title>62 Gray (MORE Than 3 Centimeter Cohort)</title>
            <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery
computed tomography: Standard CT scans
fludeoxyglucose F 18: standard doses with CT scans
hypofractionated radiation therapy: 4 doses over 2 weeks
stereotactic radiosurgery: CyberKnife radiosurgery</description>
          </group>
          <group group_id="O3">
            <title>68 Gray (MORE Than 3 Centimeter Cohort)</title>
            <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery
computed tomography: Standard CT scans
fludeoxyglucose F 18: standard doses with CT scans
hypofractionated radiation therapy: 4 doses over 2 weeks
stereotactic radiosurgery: CyberKnife radiosurgery</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose - More Than 3 Centimeter Cohort.</title>
          <description>The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.</description>
          <population>The highest tolerable dose between 56 gray, 62 gray and 68 gray has not been established as the protocol was terminated early.</population>
          <units_analyzed>dose</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>dose</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Positron Emission Tomography (PET) Response and Local Control and Survival</title>
        <description>Relationship between positron emission tomography (PET) response and local control and survival as measured by fludeoxyglucose F 18 PET/CT imaging</description>
        <time_frame>before treatment and at 1, 3, 6, and 12 months after treatment</time_frame>
        <population>Data were not collected and the outcome measure was not analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>CyberKnife</title>
            <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Positron Emission Tomography (PET) Response and Local Control and Survival</title>
          <description>Relationship between positron emission tomography (PET) response and local control and survival as measured by fludeoxyglucose F 18 PET/CT imaging</description>
          <population>Data were not collected and the outcome measure was not analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>56 Gray (LESS Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
        <group group_id="E2">
          <title>62 Gray (LESS Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
        <group group_id="E3">
          <title>68 Gray (LESS Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
        <group group_id="E4">
          <title>56 Gray (MORE Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
        <group group_id="E5">
          <title>62 Gray (MORE Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
        <group group_id="E6">
          <title>68 Gray (MORE Than 3 Centimeter Cohort)</title>
          <description>Intervention:
Procedure/Surgery: computed tomography Standard CT scans
Intervention:
Radiation: fludeoxyglucose F 18 standard doses with CT scans
Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray
Radiation: stereotactic radiosurgery CyberKnife radiosurgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>gait/walking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Forced Expiratory Volume in One Second (FEV1)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diffusing capacity of the lungs for carbon monoxide (DLCO)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <description>Presented to Emergency Department with chest pain. Treated for non-ST segment elevation myocardial infarction) - Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection-other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>gait/walking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>fibrosis-deep connective tissue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>musculoskeletal-other</sub_title>
                <description>left sided muscle soreness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>voice changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The highest tolerable dose was not established in either cohort due to early termination. There were no dose limiting toxicities experienced at 56 or 62 gray (less than 3 centimeters) or 56 gray (more than 3 centimeters) at the time of study closure</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Minh Tam Truong</name_or_title>
      <organization>Boston Medical Center</organization>
      <phone>617-638-7070</phone>
      <email>minh-tam.truong@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

